Nabriva Therapeutics AG (NBRV) Given Average Rating of “Buy” by Analysts

Shares of Nabriva Therapeutics AG (NASDAQ:NBRV) have earned a consensus recommendation of “Buy” from the nine research firms that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and seven have given a buy recommendation to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $20.43.

Several equities analysts have recently weighed in on the stock. SunTrust Banks, Inc. assumed coverage on shares of Nabriva Therapeutics AG in a research note on Friday, August 25th. They issued a “buy” rating and a $20.00 price target on the stock. Cantor Fitzgerald reissued a “buy” rating and issued a $16.00 price target on shares of Nabriva Therapeutics AG in a research note on Friday, September 1st. Zacks Investment Research downgraded shares of Nabriva Therapeutics AG from a “hold” rating to a “sell” rating in a research note on Wednesday, July 12th. HC Wainwright raised their price target on shares of Nabriva Therapeutics AG from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday, November 1st. Finally, Needham & Company LLC reissued a “buy” rating and issued a $18.00 price target (up from $15.00) on shares of Nabriva Therapeutics AG in a research note on Tuesday, September 19th.

Nabriva Therapeutics AG (NASDAQ NBRV) opened at $5.64 on Thursday. Nabriva Therapeutics AG has a twelve month low of $3.52 and a twelve month high of $14.10.

Nabriva Therapeutics AG (NASDAQ:NBRV) last posted its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.54) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($5.83) by $5.29. The business had revenue of $1.05 million during the quarter, compared to analysts’ expectations of $1.34 million. equities research analysts forecast that Nabriva Therapeutics AG will post -2.35 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This report was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this report on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this report can be accessed at https://ledgergazette.com/2017/11/09/nabriva-therapeutics-ag-nbrv-given-average-rating-of-buy-by-analysts.html.

In related news, major shareholder Hbm Healthcare Investments (Ca sold 36,608 shares of the firm’s stock in a transaction dated Thursday, September 14th. The shares were sold at an average price of $8.56, for a total transaction of $313,364.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Vivo Capital Viii, Llc acquired 52,631 shares of the business’s stock in a transaction that occurred on Monday, September 18th. The shares were purchased at an average price of $9.46 per share, with a total value of $497,889.26. The disclosure for this purchase can be found here. Over the last 90 days, insiders have purchased 57,219 shares of company stock valued at $535,919. 2.75% of the stock is owned by company insiders.

A number of institutional investors have recently added to or reduced their stakes in NBRV. Almanack Investment Partners LLC. increased its position in Nabriva Therapeutics AG by 482.2% during the second quarter. Almanack Investment Partners LLC. now owns 907,183 shares of the biotechnology company’s stock worth $1,633,000 after purchasing an additional 751,366 shares during the last quarter. Commonwealth Equity Services Inc increased its position in Nabriva Therapeutics AG by 109.7% during the third quarter. Commonwealth Equity Services Inc now owns 26,760 shares of the biotechnology company’s stock worth $219,000 after purchasing an additional 14,000 shares during the last quarter. Royal Bank of Canada increased its position in Nabriva Therapeutics AG by 19.6% during the second quarter. Royal Bank of Canada now owns 52,807 shares of the biotechnology company’s stock worth $553,000 after purchasing an additional 8,650 shares during the last quarter. Finally, Nationwide Fund Advisors increased its position in Nabriva Therapeutics AG by 4.6% during the second quarter. Nationwide Fund Advisors now owns 180,924 shares of the biotechnology company’s stock worth $2,032,000 after purchasing an additional 7,924 shares during the last quarter. Hedge funds and other institutional investors own 50.24% of the company’s stock.

Nabriva Therapeutics AG Company Profile

Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin.

Analyst Recommendations for Nabriva Therapeutics AG (NASDAQ:NBRV)

Receive News & Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply